Search

Your search keyword '"Ehrencrona H."' showing total 262 results

Search Constraints

Start Over You searched for: Author "Ehrencrona H." Remove constraint Author: "Ehrencrona H."
262 results on '"Ehrencrona H."'

Search Results

1. Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

2. Genetic counselling legislation and practice in cancer in EU Member States

3. Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing

6. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

7. Implementing precision medicine in a regionally organized healthcare system in Sweden

16. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

17. The spectrum of fancm protein truncating variants in European breast cancer cases.

18. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

19. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families.

20. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

21. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

22. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

23. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

25. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

26. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

27. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

28. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

29. Individuals with &ITFANCM&IT biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

30. The BRCA1 c. 5096G > A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

31. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

32. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

33. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

34. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

35. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

36. CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS

37. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

38. Stopping Tyrosine Kinase Inhibitors In A Very Large Cohort Of European Chronic Myeloid Leukemia Patients : Results Of The Euro-Ski Trial

39. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

40. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

41. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

42. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

43. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

44. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

45. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

46. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

47. Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

48. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers

49. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2

50. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

Catalog

Books, media, physical & digital resources